Cargando…

Efficacy of a Turkey Herpesvirus Vectored Newcastle Disease Vaccine against Genotype VII.1.1 Virus: Challenge Route Affects Shedding Pattern

The control of Newcastle disease (ND) highly relies on vaccination. Immunity provided by a ND vaccine can be characterized by measuring the level of clinical protection and reduction in challenge virus shedding. The extent of shedding depends a lot on the characteristics of vaccine used and the qual...

Descripción completa

Detalles Bibliográficos
Autores principales: Palya, Vilmos, Tatár-Kis, Tímea, Arafa, Abdel Satar A., Felföldi, Balázs, Mató, Tamás, Setta, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826937/
https://www.ncbi.nlm.nih.gov/pubmed/33440698
http://dx.doi.org/10.3390/vaccines9010037
_version_ 1783640639864307712
author Palya, Vilmos
Tatár-Kis, Tímea
Arafa, Abdel Satar A.
Felföldi, Balázs
Mató, Tamás
Setta, Ahmed
author_facet Palya, Vilmos
Tatár-Kis, Tímea
Arafa, Abdel Satar A.
Felföldi, Balázs
Mató, Tamás
Setta, Ahmed
author_sort Palya, Vilmos
collection PubMed
description The control of Newcastle disease (ND) highly relies on vaccination. Immunity provided by a ND vaccine can be characterized by measuring the level of clinical protection and reduction in challenge virus shedding. The extent of shedding depends a lot on the characteristics of vaccine used and the quality of vaccination, but influenced also by the genotype of the challenge virus. We demonstrated that vaccination of SPF chicks with recombinant herpesvirus of turkey expressing the F-gene of genotype I ND virus (rHVT-ND) provided complete clinical protection against heterologous genotype VII.1.1 ND virus strain and reduced challenge virus shedding significantly. 100% of clinical protection was achieved already by 3 weeks of age, irrespective of the challenge route (intra-muscular or intra-nasal) and vaccination blocked cloacal shedding almost completely. Interestingly, oro-nasal shedding was different in the two challenge routes: less efficiently controlled following intra-nasal than intra-muscular challenge. Differences in the shedding pattern between the two challenge routes indicate that rHVT-ND vaccine induces strong systemic immunity, that is capable to control challenge virus dissemination in the body (no cloacal shedding), even when it is a heterologous strain, but less efficiently, although highly significantly (p < 0.001) suppresses the local replication of the challenge virus in the upper respiratory mucosa and consequent oro-nasal shedding.
format Online
Article
Text
id pubmed-7826937
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78269372021-01-25 Efficacy of a Turkey Herpesvirus Vectored Newcastle Disease Vaccine against Genotype VII.1.1 Virus: Challenge Route Affects Shedding Pattern Palya, Vilmos Tatár-Kis, Tímea Arafa, Abdel Satar A. Felföldi, Balázs Mató, Tamás Setta, Ahmed Vaccines (Basel) Article The control of Newcastle disease (ND) highly relies on vaccination. Immunity provided by a ND vaccine can be characterized by measuring the level of clinical protection and reduction in challenge virus shedding. The extent of shedding depends a lot on the characteristics of vaccine used and the quality of vaccination, but influenced also by the genotype of the challenge virus. We demonstrated that vaccination of SPF chicks with recombinant herpesvirus of turkey expressing the F-gene of genotype I ND virus (rHVT-ND) provided complete clinical protection against heterologous genotype VII.1.1 ND virus strain and reduced challenge virus shedding significantly. 100% of clinical protection was achieved already by 3 weeks of age, irrespective of the challenge route (intra-muscular or intra-nasal) and vaccination blocked cloacal shedding almost completely. Interestingly, oro-nasal shedding was different in the two challenge routes: less efficiently controlled following intra-nasal than intra-muscular challenge. Differences in the shedding pattern between the two challenge routes indicate that rHVT-ND vaccine induces strong systemic immunity, that is capable to control challenge virus dissemination in the body (no cloacal shedding), even when it is a heterologous strain, but less efficiently, although highly significantly (p < 0.001) suppresses the local replication of the challenge virus in the upper respiratory mucosa and consequent oro-nasal shedding. MDPI 2021-01-11 /pmc/articles/PMC7826937/ /pubmed/33440698 http://dx.doi.org/10.3390/vaccines9010037 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Palya, Vilmos
Tatár-Kis, Tímea
Arafa, Abdel Satar A.
Felföldi, Balázs
Mató, Tamás
Setta, Ahmed
Efficacy of a Turkey Herpesvirus Vectored Newcastle Disease Vaccine against Genotype VII.1.1 Virus: Challenge Route Affects Shedding Pattern
title Efficacy of a Turkey Herpesvirus Vectored Newcastle Disease Vaccine against Genotype VII.1.1 Virus: Challenge Route Affects Shedding Pattern
title_full Efficacy of a Turkey Herpesvirus Vectored Newcastle Disease Vaccine against Genotype VII.1.1 Virus: Challenge Route Affects Shedding Pattern
title_fullStr Efficacy of a Turkey Herpesvirus Vectored Newcastle Disease Vaccine against Genotype VII.1.1 Virus: Challenge Route Affects Shedding Pattern
title_full_unstemmed Efficacy of a Turkey Herpesvirus Vectored Newcastle Disease Vaccine against Genotype VII.1.1 Virus: Challenge Route Affects Shedding Pattern
title_short Efficacy of a Turkey Herpesvirus Vectored Newcastle Disease Vaccine against Genotype VII.1.1 Virus: Challenge Route Affects Shedding Pattern
title_sort efficacy of a turkey herpesvirus vectored newcastle disease vaccine against genotype vii.1.1 virus: challenge route affects shedding pattern
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826937/
https://www.ncbi.nlm.nih.gov/pubmed/33440698
http://dx.doi.org/10.3390/vaccines9010037
work_keys_str_mv AT palyavilmos efficacyofaturkeyherpesvirusvectorednewcastlediseasevaccineagainstgenotypevii11viruschallengerouteaffectssheddingpattern
AT tatarkistimea efficacyofaturkeyherpesvirusvectorednewcastlediseasevaccineagainstgenotypevii11viruschallengerouteaffectssheddingpattern
AT arafaabdelsatara efficacyofaturkeyherpesvirusvectorednewcastlediseasevaccineagainstgenotypevii11viruschallengerouteaffectssheddingpattern
AT felfoldibalazs efficacyofaturkeyherpesvirusvectorednewcastlediseasevaccineagainstgenotypevii11viruschallengerouteaffectssheddingpattern
AT matotamas efficacyofaturkeyherpesvirusvectorednewcastlediseasevaccineagainstgenotypevii11viruschallengerouteaffectssheddingpattern
AT settaahmed efficacyofaturkeyherpesvirusvectorednewcastlediseasevaccineagainstgenotypevii11viruschallengerouteaffectssheddingpattern